Videos

Clostridioides difficile (CDI) and recurrence can create a tremendous burden on patients’ quality of life as well as become a financial burden to individual healthcare systems thus creating downstream costs for individual hospitals.

A new Infectious Diseases Society of America (IDSA) board member and vice president offers some insights on the leadership’s goals and direction for 2023.

One clinician offers some insights on the RSV surge witnessed last year and the prospective benefits of having a maternal vaccine to protect newborns from this virus.

A look back on some of the significant discussions with clinicians, researchers, and infectious disease stakeholders.

The New Drug Application (NDA) for the company’s investigational therapy, Olorofim, looks to serve an unmet medical need in this treatment space.

The Wistar Institute’s research on DNA-encoded SARs-CoV-2 monoclonal antibodies (DMAbs) allowed it to advance to clinical trials. One researcher explains how it differs from the mRNA platform.

Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.

Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment option, it’s a promise of safety and standardization.

In episode 1 of this short video series, a clinician discusses what types of patients are best suited for inpatient or outpatient care for these infections.

Dr. Tosin Goje explains the promise of ibrexafungerp for clearing yeast infection and improving quality of life for these patients.

A clinician offers his perspective on what he sees as a clinician and trial investigator in terms of what is in the pipeline and both the encouraging data and uncertainty in therapy development overall.

Young women who binge drink, and especially those who use multiple substances, had a higher risk of COVID-19 infection and mental health complications.

One clinician discusses strategies in how his institution minimizes the wide spectrum approach to antibiotics as well as tries to prevent potential complications.

An ICU hospitalist talks about his criteria and the treatment protocols for these cases.

Dynavax reported results from its phase 1 study looking at its (Tdap-1018 CpG Adjuvanted) Tetanus/Diphtheria/Pertussis booster vaccine.

In episode 1 of this short video series, a clinician discusses his experience in what his institution is seeing as well as how they handle their treatment protocol and stewardship where possible.

Studies suggest young women’s substance use is catching up to men's. Tammy Chung, PhD, examined whether this was exacerbated by the COVID-19 pandemic.

Frontier Biotechnologies reported data from its phase 1 trial for its investigational therapy, FB2001, for patients exposed to the virus.

In communities of color, hesitancy, mistrust, and access issues all drove low COVID-19 vaccination rates during the pandemic.

Is it safe and beneficial to administer a second immunomodulator in patients with moderate COVID-19? How do we identify which patients are likely to progress to severe disease?

Lodise breaks down significant findings from his 8 IDWeek 2022 posters.

Remdesivir was the first FDA-approved drug to fight COVID-19, but how has it held up against the latest variants?

Northwestern Medicine developed a testing strategy using a two-step algorithm to improve diagnostic accuracy and treatment outcomes.

One HIV clinical care program in Delaware looked into strategies to increase immunization rates to decrease severe disease as well as minimize hospital capacity.

Entasis presented follow-up data for its therapy, sulbactam-durlobactam (SUL-DUR), and its phase 3 ATTACK trial. The company is looking at a potential mid-2023 regulatory approval.

Encouraging ICU physicians to utilize rapid diagnostics, like the FilmArray Pneumonia Panel, may improve patient outcomes.

Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in an hour.

A multicenter, retrospective observational study looked at appropriate antibiotics for the treatment in this patient population.